Virios therapeutics announces initial fda feedback on proposed imc-1 phase 3 program for treatment of fibromyalgia

-virios' imc-1 phase 3 proposed program is considered acceptable based on initial fda feedback pending review of the final chronic toxicology program results-

VIRI Ratings Summary

VIRI Quant Ranking